 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
59 News |  |
- | Journal, Epigenetic controller: Assessment of alterations in histone modification function and guidance for death risk prediction in cervical cancer patients. (Pubmed Central) - Oct 7, 2022
Patients with high HMAG scores were more suitable for the treatment of CHIR-99021, embelin, FTI-277, JNK-9L, JQ12, midostaurin, PF-562271, pyrimethamine, and thapsigargin, and patients with low HMAG scores were more suitable for the treatment of BMS-536924, CP466722, crizotinib, PHA-665752, rapamycin, and TAE684. We comprehensively evaluated the histone modification status in cervical cancer patients and revealed histone modification-associated prognostic genes to construct the HMAG signature, aiming to provide a new insight into prognosis prediction and precise clinical treatment.
- | RG6146 / Roche
Preclinical, Journal: A highly selective probe for ratiometric imaging peroxynitrite in living cells and in vivo. (Pubmed Central) - Sep 14, 2022
Meanwhile, JQ-2 can be used for diagnosing drug-induced liver injury by visualizing and monitoring the fluctuations of endogenous ONOO. Therefore, JQ-2 provided a potential tool for precisely detecting the fluctuation of ONOO in biological systems to understand physiological and pathological process.
- | RG6146 / Roche
Journal: Agronomic and metabolomics analysis of rice-Tartary buckwheat (Fagopyrum tataricum Gaertn) bred by hybridization. (Pubmed Central) - Jul 23, 2022
In this study, the first hybrid rice-Tartary buckwheat (RTB) variety Mikuqiao18 (M18), bred by the pedigree selection of crossbreeding 'Miqiao' (MQ) with 'Jingqiaomai2' (JQ2), was selected for an agronomic and metabolomics analysis...In addition, M18 was abundant in 4-aminobutyric acid, which is beneficial to human health. The current findings offer a theoretical foundation for breeding rice-Tartary buckwheat with high yield and quality and promoting the cultivation and consumption of rice-Tartary buckwheat as a daily functional cereal.
- || RG6146 / Roche
Clinical, P1 data, Journal: A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. (Pubmed Central) - Feb 5, 2022
The current findings offer a theoretical foundation for breeding rice-Tartary buckwheat with high yield and quality and promoting the cultivation and consumption of rice-Tartary buckwheat as a daily functional cereal. No abstract available
- || Venclexta (venetoclax) / Roche, AbbVie, RG6146 / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P1 data, Journal: Phase Ib study of BET inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. (Pubmed Central) - Dec 1, 2021
P1
Complete response was observed in 8 patients (20.5%). Optimization of the treatment schedule and a better understanding of predictors of response would be needed to support broader clinical use.
- |||||| RG6146 / Roche
Clinical: #Myeloma Paper of the Day: A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced #myeloma finds 16.7% response rate (4/24 PRs) with brief duration of response: https://t.co/Ryh6rgSKwa. (Twitter) - Sep 4, 2021
- || RG6146 / Roche
Clinical, Journal: A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. (Pubmed Central) - Jul 21, 2021
P1
For MDS, two patients experienced SD. Further development of RO as monotherapy was discontinued due to lack of efficacy, but combinations with other agents are under consideration.
- || RG6146 / Roche
Clinical, P1 data, Journal: A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. (Pubmed Central) - Jul 16, 2021
P1
Responses in patients with NC, other solid tumours and DLBCL provide proof-of-principle for BET inhibition in MYC-driven cancers. The results support further exploration of RO6870810 as monotherapy and in combinations.
- RG6146 / Roche, Tecentriq (atezolizumab) / Roche
[VIRTUAL] Dose-Finding / Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC) () - Mar 11, 2021 - Abstract #AACR2021AACR_1969;
P1
A limited anti-tumor activity was observed with PR as best overall response in 2 pts. The trial was terminated early due to the unfavorable risk-benefit profile.
- ||||| RG6146 / Roche
Clinical, PK/PD data: @GShapiroMDPhD and colleagues published a new research last month on a Phase 1 trial which establishes the safety, favourable pharmacokinetics, evidence of target engagement, and preliminary single-agent activity of RO6870810. https://t.co/ZYyKQULv4i #CancerTherapy (Twitter) - Feb 3, 2021
- RG6146 / Roche, Darzalex IV (daratumumab) / J&J
[VIRTUAL] Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4009;
P1
Pharmacodynamics effects were evident at this dose, but as monotherapy in this R/R MM cohort, response rates were low and less durable. Future drug combination approaches may result in an improved benefit / risk ratio.
- RG6146 / Roche
Sensitizing cancer cells to TNF induced cell death by the BET-inhibitor RG6146 (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1006;
Even though treatment of this co-culture with the CEATCB alone increased bystander killing of cancer cells expressing low CEA levels, addition of RG6146 significantly enhanced this effect.We used syngeneic recipient mice to validate our findings in vivo. While single agent treatment of CEATCB or BETi decreased tumor growth, the combination of both molecules caused tumor regression.Taken together this data establishes a paradigm where BETi can rewire NF-κB signaling, leading to enhanced sensitivity to cytotoxic lymphocyte-derived TNF and therapeutically augmenting the anti-tumor activity of IO agents.
- || Venclexta (venetoclax) / Roche, AbbVie, RG6146 / Roche, Rituxan (rituximab) / Roche
Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (clinicaltrials.gov) - Jan 15, 2020
P1, N=39, Completed, Sponsor: Hoffmann-La Roche
While single agent treatment of CEATCB or BETi decreased tumor growth, the combination of both molecules caused tumor regression.Taken together this data establishes a paradigm where BETi can rewire NF-κB signaling, leading to enhanced sensitivity to cytotoxic lymphocyte-derived TNF and therapeutically augmenting the anti-tumor activity of IO agents. Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Aug 2019 | Trial primary completion date: Mar 2020 --> Aug 2019
- || RG6146 / Roche
Trial completion, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Jan 15, 2020
P1, N=24, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Aug 2019 | Trial primary completion date: Mar 2020 --> Aug 2019 Active, not recruiting --> Completed
- ||| $RHHBY discontinuations: RG6109 undiscl ADC; RG6123 anti-CEA MAb; RG6146 bromodomain inh; RG6148 undisclosed (Her2+ breast cancer); RG7625 cathepsin S inh (Twitter) - Oct 16, 2019
- | RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 11, 2019
P1, N=36, Terminated, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=116 --> 36 | Trial completion date: Jan 2021 --> May 2019 | Suspended --> Terminated | Trial primary completion date: Jan 2021 --> May 2019; Portfolio prioritization
- || Venclexta (venetoclax) / Roche, AbbVie, RG6146 / Roche, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change: A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (clinicaltrials.gov) - May 31, 2019
P1, N=39, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=116 --> 36 | Trial completion date: Jan 2021 --> May 2019 | Suspended --> Terminated | Trial primary completion date: Jan 2021 --> May 2019; Portfolio prioritization Recruiting --> Active, not recruiting | N=94 --> 39
- || RG6146 / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - May 31, 2019
P1, N=24, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=94 --> 39 Recruiting --> Active, not recruiting | N=86 --> 24
- || RG6146 / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - May 16, 2019
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=86 --> 24 Trial completion date: May 2021 --> Sep 2019 | Trial primary completion date: May 2021 --> Sep 2019
- || RG6146 / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2019
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: May 2021 --> Sep 2019 | Trial primary completion date: May 2021 --> Sep 2019 Trial completion date: Jun 2020 --> May 2021 | Trial primary completion date: Jun 2020 --> May 2021
- |||| RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Trial suspension, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 24, 2019
P1, N=116, Suspended, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2020 --> May 2021 | Trial primary completion date: Jun 2020 --> May 2021 Recruiting --> Suspended
- || RG6146 / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2019
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Venclexta (venetoclax) / Roche, AbbVie, RG6146 / Roche, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (clinicaltrials.gov) - Nov 26, 2018
P1, N=94, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
- | RG6146 / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Oct 26, 2018
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020 Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019
- | RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 24, 2018
P1, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019 Trial completion date: Jul 2020 --> Jan 2021 | Trial primary completion date: Jul 2020 --> Jan 2021
- | RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 26, 2018
P1, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2020 --> Jan 2021 | Trial primary completion date: Jul 2020 --> Jan 2021 N=30 --> 116
- || RG6146 / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - May 31, 2018
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 116 Trial completion date: Jan 2020 --> Mar 2019 | Trial primary completion date: Jan 2020 --> Mar 2019
- RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 25, 2018
P1, N=30, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2020 --> Mar 2019 | Trial primary completion date: Jan 2020 --> Mar 2019 Trial completion date: Jan 2023 --> Jul 2020 | Trial primary completion date: Jan 2023 --> Jul 2020
- RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 20, 2018
P1, N=30, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2023 --> Jul 2020 | Trial primary completion date: Jan 2023 --> Jul 2020 Trial completion date: Oct 2020 --> Jan 2023 | Trial primary completion date: Oct 2020 --> Jan 2023
- RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 18, 2017
P1, N=30, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Oct 2020 --> Jan 2023 | Trial primary completion date: Oct 2020 --> Jan 2023 Trial primary completion date: Sep 2019 --> Sep 2020
- || RG6146 / Roche
Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Dec 11, 2017
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2019 --> Sep 2020 Trial primary completion date: May 2019 --> Jan 2020
- ||| RG6146 / Roche
Trial completion, Enrollment change, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Dec 5, 2017
P1, N=52, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2019 --> Jan 2020 Active, not recruiting --> Completed | N=120 --> 52
- | RG6146 / Roche
Trial completion, Enrollment change, Trial primary completion date: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 14, 2017
P1, N=26, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=120 --> 52 Recruiting --> Completed | N=51 --> 26 | Trial primary completion date: Jan 2018 --> Aug 2017
- || RG6146 / Roche
Trial primary completion date, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Nov 14, 2017
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=51 --> 26 | Trial primary completion date: Jan 2018 --> Aug 2017 Trial primary completion date: Jan 2020 --> May 2019
- RG6146 / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 6, 2017
P1, N=30, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2020 --> May 2019 Not yet recruiting --> Recruiting
- | RG6146 / Roche, Tecentriq (atezolizumab) / Roche
PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 24, 2017
P1, N=30, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Venclexta (venetoclax) / Roche, AbbVie, RG6146 / Roche, Rituxan (rituximab) / Roche
New P1 trial: A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (clinicaltrials.gov) - Aug 21, 2017
P1, N=94, Recruiting, Sponsor: Hoffmann-La Roche
- || RG6146 / Roche
Enrollment change, Trial primary completion date: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P1, N=51, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018
- ||| RG6146 / Roche
Enrollment open, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Apr 24, 2017
P1, N=86, Recruiting, Sponsor: Hoffmann-La Roche
N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018 Not yet recruiting --> Recruiting
- || RG6146 / Roche
Enrollment closed, Trial primary completion date, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Apr 7, 2017
P1, N=120, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- ||| RG6146 / Roche
New P1 trial, Combination therapy, Metastases: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (clinicaltrials.gov) - Feb 28, 2017
P1, N=86, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || RG6146 / Roche
Trial primary completion date, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Sep 2, 2016
P1, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: May 2017 --> Aug 2017
- RG6146 / Roche
Enrollment change: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 11, 2016
P1, N=37, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2017 --> Aug 2017 N=68 --> 37
- || RG6146 / Roche
Enrollment change, Trial primary completion date, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Aug 9, 2016
P1, N=120, Recruiting, Sponsor: Hoffmann-La Roche
N=68 --> 37 N=66 --> 120 | Trial primary completion date: Mar 2016 --> May 2017
- || RG6146 / Roche
Trial primary completion date, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Mar 2, 2015
P1, N=66, Recruiting, Sponsor: Tensha Therapeutics
N=66 --> 120 | Trial primary completion date: Mar 2016 --> May 2017 Trial primary completion date: Feb 2015 --> Mar 2016
- ||| RG6146 / Roche
New P1 trial: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 6, 2014
P1, N=68, Recruiting, Sponsor: Tensha Therapeutics
- ||| RG6146 / Roche
New P1 trial, Metastases: A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (clinicaltrials.gov) - Nov 17, 2013
P1, N=66, Recruiting, Sponsor: Tensha Therapeutics